These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 26363857)

  • 1. [Incidence of admissions due to pneumonia in children under 24 months old before and after the introduction of the 10-valent pneumococcal conjugate vaccine into the National Immunization Program of Chile].
    Fernández V JP; Goecke H C; von Borries C; Tapia R N; Santolaya de P ME
    Rev Chil Pediatr; 2015; 86(3):168-72. PubMed ID: 26363857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hospitalized children with pneumonia in Uruguay: pre and post introduction of 7 and 13-valent pneumococcal conjugated vaccines into the National Immunization Program.
    Hortal M; Estevan M; Laurani H; Iraola I; Meny M;
    Vaccine; 2012 Jul; 30(33):4934-8. PubMed ID: 22664222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of the 10-Valent Pneumococcal Conjugate Vaccine (PCV-10) in Children in Chile: A Nested Case-Control Study Using Nationwide Pneumonia Morbidity and Mortality Surveillance Data.
    Diaz J; Terrazas S; Bierrenbach AL; Toscano CM; Alencar GP; Alvarez A; Valenzuela MT; Andrus J; del Aguila R; Hormazábal JC; Araya P; Pidal P; Matus CR; de Oliveira LH
    PLoS One; 2016; 11(4):e0153141. PubMed ID: 27058873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in hospitalizations for pneumonia after universal vaccination with pneumococcal conjugate vaccines 7/13 valent and haemophilus influenzae type b conjugate vaccine in a Pediatric Referral Hospital in Uruguay.
    Pírez MC; Algorta G; Chamorro F; Romero C; Varela A; Cedres A; Giachetto G; Montano A
    Pediatr Infect Dis J; 2014 Jul; 33(7):753-9. PubMed ID: 24492286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the pneumococcal 10-valent vaccine on reducing hospitalization for community-acquired pneumonia in children.
    Silva SR; Mello LM; Silva AS; Nunes AA
    Rev Paul Pediatr; 2016 Dec; 34(4):418-424. PubMed ID: 27108092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) on childhood pneumonia hospitalizations in Brazil two years after introduction.
    Scotta MC; Veras TN; Klein PC; Tronco V; Polack FP; Mattiello R; Pitrez PMC; Jones MH; Stein RT; Pinto LA
    Vaccine; 2014 Jul; 32(35):4495-4499. PubMed ID: 24958703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of heptavalent pneumococcal conjugate vaccine on the incidence of childhood community-acquired pneumonia and bacteriologically confirmed pneumococcal pneumonia in Japan.
    Naito S; Tanaka J; Nagashima K; Chang B; Hishiki H; Takahashi Y; Oikawa J; Nagasawa K; Shimojo N; Ishiwada N
    Epidemiol Infect; 2016 Feb; 144(3):494-506. PubMed ID: 26122538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent invasive pneumococcal disease in children--host factors and vaccination response.
    Ingels HA
    Dan Med J; 2015 Jul; 62(7):. PubMed ID: 26183055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of Acute Otitis Media in Children Under 24 Months of Age Before and After the Introduction of the 10-valent Pneumococcal Conjugate Vaccine Into the National Immunization Program in Chile.
    Rosenblut A; Rosenblut M; García K; Maul X; Santolaya ME
    Pediatr Infect Dis J; 2018 Feb; 37(2):132-134. PubMed ID: 28763425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis.
    Grijalva CG; Nuorti JP; Arbogast PG; Martin SW; Edwards KM; Griffin MR
    Lancet; 2007 Apr; 369(9568):1179-86. PubMed ID: 17416262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotype distribution of Streptococcus pneumoniae isolated from patients with invasive pneumococcal disease in Brazil before and after ten-pneumococcal conjugate vaccine implementation.
    dos Santos SR; Passadore LF; Takagi EH; Fujii CM; Yoshioka CR; Gilio AE; Martinez MB
    Vaccine; 2013 Dec; 31(51):6150-4. PubMed ID: 23747454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early impact of 10-valent pneumococcal conjugate vaccine in childhood pneumonia hospitalizations using primary data from an active population-based surveillance.
    Sgambatti S; Minamisava R; Bierrenbach AL; Toscano CM; Vieira MA; Policena G; Andrade AL
    Vaccine; 2016 Jan; 34(5):663-670. PubMed ID: 26706272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children <5 years.
    Greenberg D; Givon-Lavi N; Ben-Shimol S; Ziv JB; Dagan R
    Vaccine; 2015 Aug; 33(36):4623-9. PubMed ID: 26116251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hospitalizations for pneumonia, invasive diseases and otitis in Tuscany (Italy), 2002-2014: Which was the impact of universal pneumococcal pediatric vaccination?
    Boccalini S; Varone O; Chellini M; Pieri L; Sala A; Berardi C; Bonanni P; Bechini A
    Hum Vaccin Immunother; 2017 Feb; 13(2):428-434. PubMed ID: 27925848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada.
    De Wals P; Robin E; Fortin E; Thibeault R; Ouakki M; Douville-Fradet M
    Pediatr Infect Dis J; 2008 Nov; 27(11):963-8. PubMed ID: 18845982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the emergence of non-vaccine pneumococcal serotypes on the clinical presentation and outcome of adults with invasive pneumococcal pneumonia.
    Burgos J; Falcó V; Borrego A; Sordé R; Larrosa MN; Martinez X; Planes AM; Sánchez A; Palomar M; Rello J; Pahissa A
    Clin Microbiol Infect; 2013 Apr; 19(4):385-91. PubMed ID: 22583156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pneumonia hospitalizations of children aged <2 years in Poland before (2013-2016) and after (2017-2018) universal mass vaccination with 10-valent pneumococcal non-typeable
    Bhavsar A; Zaryczański J; Wasilewska A; Saragoussi D; Devadiga R; Colby C; Bahar E; Wysocki J
    Hum Vaccin Immunother; 2022 Nov; 18(6):2128566. PubMed ID: 36239615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of a combined pediatric and adult pneumococcal immunization program on adult pneumonia incidence and mortality in Nicaragua.
    Becker-Dreps S; Amaya E; Liu L; Rocha J; Briceño R; Moreno G; Alemán J; Hudgens MG; Woods CW; Weber DJ
    Vaccine; 2015 Jan; 33(1):222-7. PubMed ID: 25444795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema.
    Byington CL; Korgenski K; Daly J; Ampofo K; Pavia A; Mason EO
    Pediatr Infect Dis J; 2006 Mar; 25(3):250-4. PubMed ID: 16511389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of ten-valent pneumococcal conjugate vaccine on pneumonia in Finnish children in a nation-wide population-based study.
    Palmu AA; Rinta-Kokko H; Nohynek H; Nuorti JP; Kilpi TM; Jokinen J
    PLoS One; 2017; 12(3):e0172690. PubMed ID: 28249015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.